Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Plus Therapeutics Inc (USA) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
PSTV
Nasdaq
8731
http://www.plustherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Plus Therapeutics Inc (USA)
Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference
- Mar 27th, 2024 12:00 pm
Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic
- Mar 25th, 2024 12:00 pm
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases
- Mar 11th, 2024 11:00 am
Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call Transcript
- Mar 7th, 2024 1:59 pm
Plus Therapeutics Full Year 2023 Earnings: Beats Expectations
- Mar 7th, 2024 11:12 am
Q4 2023 Plus Therapeutics Inc Earnings Call
- Mar 6th, 2024 6:43 pm
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
- Mar 5th, 2024 10:35 pm
Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
- Mar 5th, 2024 9:05 pm
Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024
- Feb 27th, 2024 1:00 pm
Plus Updates Financial and Cash Guidance for 2024
- Dec 18th, 2023 12:00 pm
Plus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses
- Dec 12th, 2023 1:00 pm
Plus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit Europe
- Nov 29th, 2023 1:00 pm
Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar
- Nov 20th, 2023 12:00 pm
Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023
- Nov 15th, 2023 12:00 pm
Thinking about buying stock in Tivic Health Systems, Tigo Energy, TAT Technologies, Plus Therapeutics, or Acumen Pharmaceuticals?
- Nov 13th, 2023 2:31 pm
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastases
- Nov 3rd, 2023 11:00 am
Plus Therapeutics, Inc. (NASDAQ:PSTV) Q3 2023 Earnings Call Transcript
- Nov 1st, 2023 1:29 pm
Plus Therapeutics Announces Share Repurchase Program
- Oct 31st, 2023 8:10 pm
Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
- Oct 31st, 2023 8:05 pm
Plus Therapeutics to Present at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar
- Oct 25th, 2023 1:21 pm
Scroll